High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation

Phase IIa cross-over study of propylene glycol-free melphalan (LGD-353) and alkeran in multiple myeloma autologous transplantation

(2014) O S Aljitawi et al.   BONE MARROW TRANSPLANTATION

Autologous Transplantation and Maintenance Therapy in Multiple Myeloma

(2014) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation

(2012) Ulas D. Bayraktar et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma

(2011) Qaiser Bashir et al.   LEUKEMIA & LYMPHOMA

Treatment of multiple myeloma

(2011) S. Vincent Rajkumar   Nature Reviews Clinical Oncology

A Deletion Polymorphism in Glutathione-S-Transferase Mu (GSTM1) and/or Theta (GSTT1) Is Associated with an Increased Risk of Toxicity after Autologous Blood and Marrow Transplantation

(2010) Theresa Hahn et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy

(2010) Christa E. Nath et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study

(2009) A. Palumbo et al.   BLOOD

An isocratic UV HPLC assay for analysis of total and free melphalan concentrations in human plasma

(2008) C. Nath Nath et al.   ACTA CHROMATOGRAPHICA